Overview

  • Product nameAnti-TNF Receptor I antibodySee all TNF Receptor I primary antibodies ...
  • Description
    Rabbit polyclonal to TNF Receptor I
  • Specificityab58436 detects endogenous levels of total TNF Receptor I protein. This antibody binds to the C-terminal cytoplasmic domain and reacts with three isoforms (1, 2, and 3) of human TNF Receptor I.
  • Tested applicationsELISA, IHC-P more details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide derived from an internal sequence of human TNF Receptor I

  • Positive control
    • IHC-P: Human breast carcinoma.

Properties

Applications

Our Abpromise guarantee covers the use of ab58436 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ELISA 1/20000.
IHC-P Use at an assay dependent dilution.

Target

  • FunctionReceptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase.
  • Involvement in diseaseFamilial hibernian fever
    Multiple sclerosis 5
  • Sequence similaritiesContains 1 death domain.
    Contains 4 TNFR-Cys repeats.
  • DomainThe domain that induces A-SMASE is probably identical to the death domain. The N-SMASE activation domain (NSD) is both necessary and sufficient for activation of N-SMASE.
    Both the cytoplasmic membrane-proximal region and the C-terminal region containing the death domain are involved in the interaction with TRPC4AP.
  • Post-translational
    modifications
    The soluble form is produced from the membrane form by proteolytic processing.
  • Cellular localizationCell membrane. Golgi apparatus membrane. Secreted. A secreted form is produced through proteolytic processing and Secreted. Lacks a Golgi-retention motif, is not membrane bound and therefore is secreted.
  • Target information above from: UniProt accession P19438 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
    • CD120a antibody
    • CD120a antigen antibody
    • FPF antibody
    • MGC19588 antibody
    • p55 antibody
    • p55 R antibody
    • p55-R antibody
    • p55R antibody
    • p60 antibody
    • TBP1 antibody
    • TBPI antibody
    • TNF R antibody
    • TNF R I antibody
    • TNF R1 antibody
    • TNF R55 antibody
    • TNF-R1 antibody
    • TNF-RI antibody
    • TNFAR antibody
    • TNFR 1 antibody
    • TNFR I antibody
    • TNFR-I antibody
    • TNFR1 antibody
    • TNFR55 antibody
    • TNFR60 antibody
    • TNFRI antibody
    • TNFRSF1a antibody
    • TNR1A_HUMAN antibody
    • Tumor necrosis factor alpha receptor antibody
    • Tumor necrosis factor binding protein 1 antibody
    • Tumor necrosis factor receptor 1 antibody
    • Tumor necrosis factor receptor superfamily member 1A antibody
    • Tumor necrosis factor receptor superfamily, member 1A antibody
    • Tumor necrosis factor receptor type 1 antibody
    • Tumor necrosis factor receptor type I antibody
    • Tumor necrosis factor-binding protein 1 antibody
    see all

Anti-TNF Receptor I antibody images

  • ab58436, at 1/50 dilution, staining TNF Receptor I in paraffin embedded human breast carcinoma tissue by Immunohistochemistry in the absence (left image) or presence (right image) of the immunising peptide.

References for Anti-TNF Receptor I antibody (ab58436)

This product has been referenced in:
  • K_M_Coxon, J_Duggan, S_Nizari, L_Guo, M_F_Cordeiro Effects of Ocular Hypertension on Tumor Necrosis (TNF) Receptors and RGC Apoptosis ARVO Meeting Abstracts 51: (2010). Read more (PubMed: ) »
  • Moutsopoulos NM  et al. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 67:1437-43 (2008). IHC-P ; Human . Read more (PubMed: 18198195) »

See all 2 Publications for this product

Product Wall

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (Spleen)
Specification Spleen
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: CC1 Standard
Permeabilization No
Blocking step S Block as blocking agent for 10 minute(s) · Concentration: 100% · Temperature: 37°C
Username

Abcam user community

Verified customer

Submitted Dec 11 2012


This antibody binds to the C-terminal cytoplasmic domain and reacts with three isoforms (1, 2, and 3) of human TNF Receptor I.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"